Kuros Biosciences Ltd.

As of June 30, 2026, Kuros Biosciences Ltd. carries a market capitalization of 761.18M, placing it among publicly traded companies globally. Its enterprise value stands at 761.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Kuros Biosciences Ltd.'s next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2026, Kuros Biosciences Ltd. has 39.44M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Kuros Biosciences Ltd. maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Kuros Biosciences Ltd.'s stock has declined approximately 36.22% over the past 52 weeks. The 50-day moving average sits at 18.93, while the 200-day moving average is 21.93.

As of June 30, 2026, Kuros Biosciences Ltd. holds 7.86M in cash and equivalents against 8.13M in total debt, resulting in a net debt position of -7.86M. Total book value stands at 72.10M, with working capital of 31.29M providing operational flexibility.

Kuros Biosciences Ltd.'s most recent stock split took place on October 8, 2020 with a 761:826 split ratio.